Parabiotic Research & Development Corp.  is an early-stage company developing innovative combination drug products for the treatment of Inflammatory Bowel Disease (IBD) — Crohn’s disease and ulcerative colitis, including infectious diseases — as well as treating the symptoms of Irritable Bowel Syndrome (IBS).

Our focus is to treat an underlying cause of Inflammatory Bowel Disease, pathogenic bacteria, and to develop a new class of combination drug products that are reformulated and repurposed from generic medications and that will enhance homeostasis in the gut microbiome.

PARABIOTIC’s lead product PB-1 is a pH-dependent capsule consisting of antibiotics and a proprietary blend of probiotics encapsulated together as one single dose — that is superior to taking multiple individual pills at different intervals.

Six patents covering oral dosage forms of PB-1 and its Methods for Treatment have been granted in the US, Australia, Canada, and Mexico.

Inflammatory bowel disease affects over 8 million sufferers worldwide with the U.S. accounting for almost 2 million patients. Irritable bowel syndrome if left untreated is often a precursor to IBD for many patients. IBS accounts for over 30 million sufferers in the U.S. alone.

PARABIOTIC’s PB-1 and its Method for Treatment will offer clinicians an alternative to current treatment options that is less toxic, safer and more effective than the use of steroids and immunosuppressants — while minimizing the negative side effects of antibiotic therapy.

The vision of its Chairman and Founder who suffered for over 35 years from ulcerative colitis and who is now in remission for seven years, PARABIOTIC was founded to pursue a better way to treat this insidious disease.